托法替布治疗类风湿关节炎患者的预估医疗支出与失业风险:两项随机临床试验的事后分析
该事后分析基于两项随机III期试验(n=1115)的RA患者数据,评估托法替布5或10 mg每日两次对比安慰剂(均联合甲氨蝶呤)对月度医疗支出(MME)和失业风险的影响。结果显示,在甲氨蝶呤或TNF抑制剂应答不佳的患者中,托法替布治疗第3个月时MME较安慰剂组多降低100美元或70美元,且无法工作几率和未来失业风险均显著降低(P<0.001)。
要点
- 托法替布治疗第3个月时,TNFi应答不佳者MME较安慰剂多降低100美元(P<0.001)。
- 托法替布治疗第3个月时,MTX应答不佳者MME较安慰剂多降低70美元(P<0.001)。
- 托法替布治疗第3个月时,无法工作几率和未来失业风险均显著下降(P<0.001)。
核心结论
- 托法替布治疗对甲氨蝶呤或TNF抑制剂应答不佳的RA患者的预估医疗支出和失业风险有积极影响。
研究设计与样本
- 两项随机III期试验的事后分析,纳入1115例对甲氨蝶呤或TNF抑制剂应答不佳的RA患者,接受托法替布5或10 mg每日两次、阿达木单抗(仅一项研究)或安慰剂,均联合甲氨蝶呤。
主要发现
- TNFi应答不佳者中,托法替布组第3个月MME较安慰剂组多降低100美元(P<0.001),分别较基线降低>20%和6%。
- MTX应答不佳者中,托法替布组第3个月MME较安慰剂组多降低70美元(P<0.001),分别较基线降低≥23%和13%。
- TNFi应答不佳者中,托法替布治疗第3个月时无法工作的几率降低≥16%,未来失业风险降低约20%(P<0.001 vs 安慰剂)。
- MTX应答不佳者中,托法替布治疗第3个月时无法工作的几率降低≥31%,未来失业风险降低≥25%(P<0.001 vs 安慰剂)。
关键数值与推荐
- MME由SF-36 v2生理和心理成分总结评分通过算法转换为预测值,并结合医学结局研究数据评估6、12和24个月时无法工作和失业风险。
临床怎么用
- 对于甲氨蝶呤或TNF抑制剂应答不佳的RA患者,托法替布治疗可能有助于降低预估医疗支出和失业风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: RA causes high disability levels and reduces health-related quality of life, triggering increased costs and risk of unemployment. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. These post hoc analyses of phase 3 data aimed to assess monthly medical expenditure (MME) and risk of job loss for tofacitinib treatment vs placebo. METHODS: Data analysed were from two randomized phase 3 studies of RA patients (n = 1115) with inadequate response to MTX or TNF inhibitors (TNFi) receiving tofacitinib 5 or 10 mg twice daily, adalimumab (one study only) or placebo, in combination with MTX. Short Form 36 version 2 Health Survey physical and mental component summary scores were translated into predicted MME via an algorithm and concurrent inability to work and job loss risks at 6, 12 and 24 months, using Medical Outcomes Study data. RESULTS: MME reduction by month 3 was $100 greater for tofacitinib- than placebo-treated TNFi inadequate responders (P < 0.001); >20 and 6% reductions from baseline, respectively. By month 3 of tofacitinib treatment, the odds of inability to work decreased ⩾16%, and risk of future job loss decreased ∼20% (P < 0.001 vs placebo). MME reduction by month 3 was $70 greater for tofacitinib- than placebo-treated MTX inadequate responders (P < 0.001); ⩾23 and 13% reductions from baseline, respectively. By month 3 of tofacitinib treatment, the odds of inability to work decreased ⩾31% and risk of future job loss decreased ⩾25% (P < 0.001 vs placebo). CONCLUSION: Tofacitinib treatment had a positive impact on estimated medical expenditure and risk of job loss for RA patients with inadequate response to MTX or TNFi.
引用
- Rendas-Baum R, Kosinski M, Singh A, et al. Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials. Rheumatology (Oxford). 2017. PMID: 28460083. doi:10.1093/rheumatology/kex087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。